Health ❯ Healthcare ❯ Medical Research ❯ Oncology

Breast Cancer

NF1-Low ER+ Breast Cancers Identified as Likely Responders to CDK4/6 Inhibitors

Prospective validation and reliable NF1 protein tests are needed before the biomarker can guide prescribing.

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Low-Dose Vitamin D Supplementation Enhances Chemotherapy Success in Breast Cancer Trial